A digital video game developed by Akili Interactive Labs for treating cognitive disorders has demonstrated in a pilot study its ability to improve cognitive control test scores of neurotypical children and children with sensory processing dysfunction (SPD).
This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and AVM embolization systems. This market comprises the following product segments: endovascular coils, liquid embolics, stents for stent-assisted coiling, flow diversion and flow disruption systems, and other novel/emerging embolization devices. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets. The forecast range for this report is 2020–25.
The digitalization of health care has been much talked about over the last decade or so. But activity among the medical device manufacturers and service providers has only just recently accelerated as they start overcoming barriers and resistance to this new way of delivering health care.
> Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps > Telehealth Reforms Praised At Senate Hearing > Philips’ Survey Highlights Gaps In Perceptions Of Health Care > Game On For Akili’s Cognitive Control Tech
Sanofi plans to continue distributing Zantac OTC heartburn remedy in the US while conducting its own tests to determine whether levels of N-nitrosodimethylamine (NDMA) in the active ingredient are above safe levels, Novartis AG, which licenses OTC Zantac, has said it stopped distribution worldwide.
The 21st Century Cures Act’s call for the use of real-world evidence (RWE) is slowly moving toward reality. But hurdles abound, warns IQVIA’s Nancy Dreyer. For instance, the FDA–which is behind the EMA in this area–appears split. Privacy concerns and lack of interoperability hinder progress. Learn why this sometimes-muddied distinction between randomized clinical trial data and RWE is so important, and find out RWE’s role in label expansions.
Wearable technologies have the potential to transform medicine and the delivery of healthcare more significantly than any other component of the digital revolution – or indeed than many other scientific advances.
Biogen’s chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer’s Disease. Biogen CMO Alfred Sandrock has told a London neuroscience forum that constraints impeding CNS drug development include the fact diagnosis needs to be done earlier but that barrier could be mitigated in future by digital health solutions such iPhones used as “early warning” diagnostics, notably in Alzheimer’s Disease.
The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)
Knee and hip replacement company Corin Group PLC has acquired Omni Orthopedics Inc. The acquisition of Omni, which specializes in robotic-assisted total knee replacement, marks another major step in the company’s expansion in the orthopedic market.
Victoria Hordern and Amy Merrick discuss initiatives in the EU to help app developers navigate the unclear rules on mobile health and explain why engaging patients during product development is key.
> Behind The Scenes Of Digital Health: Medtech Players And Partners > Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care > New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector > Siemens Healthineers To Launch Digital ‘One-Stop-Shop’
Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.
> Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym > Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s > Interview: Philips Plugs Into Patient Connectivity
Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable. The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!